• Immune therapy scores big win against lung cancer in study

    3 monthes ago - By National Post

    CHICAGO - For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.
    In the study, Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year. The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has...
    Read more ...

     

  • Immune therapy scores big win against lung cancer in study

    Immune therapy scores big win against lung cancer in study

    3 monthes ago - By The Seattle Times

    CHICAGO - New research suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common forms of the disease. One study found using one of these drugs - Merck's Keytruda - with usual chemotherapy greatly...
    Read more ...